| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
AEGEA Medical was founded in 2008 to develop technology that aspires to utilize water vapor to treat a variety of women`s health conditions. Led by an experienced management team, and supported by a committed investor group, AEGEA Medical has established an expanding Intellectual Property (IP) portfolio.
Siegfried USA is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Pennsville, NJ. To find more information about Siegfried USA, please visit www.siegfried-usa.com
CCA Industries, Inc. (CCA) is engaged in the health and beauty aids business, selling numerous products in several health and beauty aids and cosmeceutical categories.
Hospice by the Sea is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.